IGHE and asthma: We recommend a proactive approach that includes the following: early biomarker assessment (blood eosinophils, FeNO, serum IgE) for all patients with moderate or symptomatic asthma, inclusion of symptom burden (even without frequent exacerbations), as a criterion for treatment escalation, escalation to biologic therapy if type 2 inflammation persists despite standard ICS/LABA therapy, regardless of exacerbation history.